Trials / Active Not Recruiting
Active Not RecruitingNCT07264205
RT-310 Safety and Feasibility BPH Study
Safety and Feasibility Study of RT-310 for Treatment of Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH)
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Resurge Therapeutics Inc. · Industry
- Sex
- Male
- Age
- 50 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
RT-310, is intended to deliver drug locally to the prostate gland for the management of prostate disease, while minimizing systemic exposure and its associated side-effects. The objectives of the study are to assess whether RT-310 is safe and feasible for the participant population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | RT-310 | RT-310 |
Timeline
- Start date
- 2025-03-13
- Primary completion
- 2026-03-01
- Completion
- 2026-06-01
- First posted
- 2025-12-04
- Last updated
- 2026-03-20
Locations
1 site across 1 country: Dominican Republic
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07264205. Inclusion in this directory is not an endorsement.